Factors Contributing to Erythropoietin Hyporesponsiveness Among Hemodialysis Patients: A Cross-Sectional Multicenter Study

Authors Information
Article Notes and Dates
To Cite : Samavat S, Nafar M, Khoshdel A, Alipour- Abedi B. Factors Contributing to Erythropoietin Hyporesponsiveness Among Hemodialysis Patients: A Cross-Sectional Multicenter Study, Nephro-Urol Mon. 2017 ;9(3):e45003. doi: 10.5812/numonthly.45003.
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Chen L, Ling YS, Lin CH, He JX, Guan TJ. High Dose ESAs Are Associated with High iPTH Levels in Hemodialysis Patients with End-Stage Kidney Disease: A Retrospective Analysis. Front Public Health. 2015; 3: 258[DOI][PubMed]
  • 2. Kuwahara M, Mandai S, Kasagi Y, Kusaka K, Tanaka T, Shikuma S, et al. Responsiveness to erythropoiesis-stimulating agents and renal survival in patients with chronic kidney disease. Clin Exp Nephrol. 2015; 19(4): 598-605[DOI][PubMed]
  • 3. Panichi V, Rosati A, Bigazzi R, Paoletti S, Mantuano E, Beati S, et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant. 2011; 26(8): 2641-8[DOI][PubMed]
  • 4. Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis. 2013; 61(1): 44-56[DOI][PubMed]
  • 5. Bamgbola O. Resistance to erythropoietin-stimulating agents: etiology, evaluation, and therapeutic considerations. Pediatr Nephrol. 2012; 27(2): 195-205[DOI][PubMed]
  • 6. Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton). 2007; 12(4): 321-30[DOI][PubMed]
  • 7. Ogawa T, Shimizu H, Kyono A, Sato M, Yamashita T, Otsuka K, et al. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study. Int Urol Nephrol. 2014; 46(1): 151-9[DOI][PubMed]
  • 8. Lopez-Gomez JM, Portoles JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl. 2008; (111)-81[DOI][PubMed]
  • 9. Gilbertson DT, Peng Y, Arneson TJ, Dunning S, Collins AJ. Comparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics. BMC Nephrol. 2013; 14: 44[DOI][PubMed]
  • 10. K DIGO. KDIGO clinical practice guideline for Anemia in chronic Kidney disease. Kidney inter. 2012; 2: 279-335
  • 11. Alves MT, Vilaca SS, Carvalho M, Fernandes AP, Dusse LM, Gomes KB. Resistance of dialyzed patients to erythropoietin. Rev Bras Hematol Hemoter. 2015; 37(3): 190-7[DOI][PubMed]
  • 12. Schneider A, Schneider MP, Scharnagl H, Jardine AG, Wanner C, Drechsler C. Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes. BMC Nephrol. 2013; 14: 67[DOI][PubMed]
  • 13. Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis. 2009; 53(5): 823-34[DOI][PubMed]
  • 14. Hara T, Mukai H, Nakashima T, Sagara R, Furusho M, Miura S, et al. Factors Contributing to Erythropoietin Hyporesponsiveness in Patients on Long-Term Continuous Ambulatory Peritoneal Dialysis: A Cross-Sectional Study. Nephron Extra. 2015; 5(3): 79-86[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiaion Alert via Google Reader

Cited By:

Nephro-Urology Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check